$BIOA

BioAge Labs, Inc.

BioAge Labs is a clinical-stage biopharmaceutical company based in Emeryville, California. It develops therapeutic candidates for metabolic diseases by targeting the biology of human aging. Its research platform analyzes human samples, health records and functional measurements to identify potential treatment targets. BioAge’s lead program, BGE-102, is an oral NLRP3 inhibitor in development for patients with cardiovascular risk factors and diabetic macular edema. The company also develops oral and subcutaneous apelin receptor APJ agonists for obesity. BioAge advances earlier-stage programs with Eli Lilly and Company and conducts target discovery in collaboration with Novartis Pharma AG.

AlphAI earnings readThird Quarter 2026 · NOV 5BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business UpdatesVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

1
0
0

No SEC Form 4 filings for $BIOA in the last 30 days.

See all $BIOA insider activity →
Med

Five-year data of continuous Leqembi® treatment show increasing benefit over time

BioArctic's partner Eisai presented five-year data from the Clarity AD study, showing continuous Leqembi treatment in early Alzheimer's disease increased clinical benefits over time. 62% of patients treated early showed cognitive improvement. Leqembi reduced cognitive decline by 2.05 points after five years compared to historic data. Eisai and BioArctic collaborate on Leqembi's development and commercialization.

BIOA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning BIOA (BioAge Labs, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent BIOA coverage spans financial news, earnings and technology.

What's driving BIOA

  • Longer-duration efficacy and no new safety signals are likely to support sentiment and valuation for BioArctic’s Leqembi franchise.

    prnewswire.com · Nov 17, 2026

  • Piper Sandler kept Bioage Labs at Overweight but cut its price target from $73 to $40, a 45.2% reduction. The new target suggests 649.1% upside from the Nov 6 close of $5.34, according to the firm.

    tradingview.com · Nov 9, 2026

  • BTIG reaffirmed its Buy rating and $40 price target for Bioage Labs, representing a 649.1% upside from the Nov 6 close of $5.34, according to the firm.

    tradingview.com · Nov 9, 2026

  • Earnings miss likely triggers sell pressure.

    seekingalpha.com · Nov 6, 2026

  • The trial progress and financial results suggest continued cash burn but advancing pipeline, likely supporting near‑term price stability with upside potential if data are positive.

    SEC EDGAR 8-K · Nov 5, 2026

AlphAI scores every news story that mentions BIOA with an AI model for sentiment and relevance, and aggregates insider trades from BioAge Labs, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BIOA

Score
$BIOAMedAI 8/10Clinical / regulatory

Five-year data of continuous Leqembi® treatment show increasing benefit over time

BioArctic's partner Eisai presented five-year data from the Clarity AD study, showing continuous Leqembi treatment in early Alzheimer's disease increased clinical benefits over time. 62% of patients treated early showed cognitive improvement. Leqembi reduced cognitive decline by 2.05 points after five years compared to historic data. Eisai and BioArctic collaborate on Leqembi's development and commercialization.

$BIOAMedEarnings

BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates

BioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the seco

About $352 million in cash and securities could fund BioAge's operations through 2029

BioAge Labs (NASDAQ: BIOA) reported $352M in cash and securities for operations through 2029. It dosed the first participant in a Phase 2 trial for BGE-102 in diabetic macular edema, with results expected in 2H 2027. The QUELL-CV Phase 2 trial for BGE-102 in obesity completed enrollment, with data due in 4Q 2026. The company aims to file an IND for its APJ agonist program by year-end 2026. BioAge also updated its collaborations with Novartis, Lilly, and Deep Origin.

$BIOAMedAI 8/10Clinical / regulatory· trial start

BioAge Labs, Inc. recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily…

BioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events BioAge Labs, Inc. (the “ Company ”) recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema (“ DME ”), an

Analysts Offer Insights on NA Companies: Fair Isaac (FICO), Freeport-McMoRan (FCX) and BioAge Labs, Inc. (BIOA)

Analysts updated ratings for NA sector companies. Clear Street's Owen Lau reiterated a Buy rating on Fair Isaac (FICO) with a $1600 price target. Freeport-McMoRan (FCX) was kept at Hold by Bernstein's Bob Brackett. BioAge Labs (BIOA) received a Buy rating from Needham's Joseph Stringer with a $35 target. Analyst consensus for FICO is Moderate Buy, FCX is Strong Buy, and BIOA is Strong Buy.

Related tickers